GH Research (GHRS) Income towards Parent Company (2020 - 2026)
GH Research (GHRS) posted quarterly Income towards Parent Company of -$14.1 million for Q4 2025, down 60.61% year-over-year from -$35.9 million in Q4 2024, and down 0.83% quarter-over-quarter from -$14.0 million in Q3 2025.
Analysis
GH Research (GHRS) Income towards Parent Company (2020 - 2026) Analysis & Trends
GH Research's Income towards Parent Company history runs 6 years deep, the most recent figure standing at -$14.1 million for Q4 2025.
- In Q4 2025, Income towards Parent Company fell 60.61% year-over-year to -$14.1 million; the TTM figure through Dec 2025 stood at -$48.3 million (down 23.86% YoY), while the FY2025 annual figure was -$48.3 million, down 23.86% from the prior year.
- Income towards Parent Company for Q4 2025 stood at -$14.1 million, down from -$14.0 million in the prior quarter.
- The five-year high for Income towards Parent Company was $334000.0 in Q2 2022, with the low at -$16.6 million in Q4 2022.
- The 5-year median for Income towards Parent Company is -$8.3 million (2023), against an average of -$7.7 million.
- The sharpest annual moves came in 2021 and 2022: Income towards Parent Company slumped 2961.67% in 2021, then surged 115.72% in 2022.
- GH Research's Income towards Parent Company stood at -$4.1 million in 2021, then slumped by 305.43% to -$16.6 million in 2022, then jumped by 32.04% to -$11.3 million in 2023, then advanced by 21.91% to -$8.8 million in 2024, then plunged by 60.61% to -$14.1 million in 2025.
- Business Quant data shows GHRS's Income towards Parent Company at -$14.1 million in Q4 2025, -$14.0 million in Q3 2025, and -$9.3 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | GH Research | 1.71 Bn | 1.35 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.15 Mn |
| Mar 31, 2026 | -18.97 Mn |
| Dec 31, 2025 | -14.14 Mn |
| Sep 30, 2025 | -14.02 Mn |
| Jun 30, 2025 | -9.29 Mn |
| Mar 31, 2025 | -10.81 Mn |
| Dec 31, 2024 | -8.80 Mn |
| Sep 30, 2024 | -12.11 Mn |
| Jun 30, 2024 | -10.38 Mn |
| Mar 31, 2024 | -7.67 Mn |
| Dec 31, 2023 | -11.27 Mn |
| Sep 30, 2023 | -5.65 Mn |
| Jun 30, 2023 | -7.73 Mn |
| Mar 31, 2023 | -10.94 Mn |
| Dec 31, 2022 | -16.59 Mn |
| Sep 30, 2022 | -441,000.00 |
| Jun 30, 2022 | 334,000.00 |
| Mar 31, 2022 | -5.76 Mn |
| Dec 31, 2021 | -4.09 Mn |
| Sep 30, 2021 | -1.84 Mn |